Release
2023/02/20
OSAKA, Japan, February 20, 2023 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that, at the meeting of its Board of Directors held today, the Directors decided to transfer a portion of the shares of Shionogi Business Partner Co., Ltd., (Head Office: Osaka, Japan; President: Yuji Hosogai; hereafter "Shionogi Business Partner"), a wholly-owned group company, to Accenture Co., Ltd. (Head Office: Tokyo, Japan; Chief Executive Officer: Atsushi Egawa; hereafter " Accenture ") to form a joint venture.
In its reorganization in July 2022, to improve business process efficiency, Shionogi merged four group companies running back office functions such as human resources, general affairs, accounting and finance into Shionogi Business Partner Co., Ltd.
In order to further accelerate business reforms and enhance the expertise of employees, we have decided to transfer 80% of Shionogi Business Partner's stock to Accenture and form a joint venture. The transfer is scheduled to be concluded on July 3, 2023. In addition, prior to the forming of this joint venture, Shionogi Pharmacovigilance Center Co., Ltd. (Head Office: Osaka, Japan; President: Masako Kaneto; hereafter "Shionogi Pharmacovigilance Center") will be absorbed into Shionogi Business Partner on July 1,2023 for the purpose of synergy with Accenture's business process managed services related to safety management operations.
By forming a joint venture with Accenture, we will utilize Accenture's strength in indirect business reform know-how to thoroughly improve efficiency. Furthermore, by learning from Accenture's know-how, we will create new opportunities for the professional growth and development of the employees, enabling them to play a greater role in the growth and development of Shionogi Group's business.
Together with Shionogi Business Partner and Shionogi Pharmacovigilance Center, Accenture and Shionogi will continue working on the finer details of the establishment ahead of the planned July launch.
Outline of the joint venture
Corporate Name |
Shionogi Business Partner Company Limited [SBP] |
Location |
7-6, Doshomachi 4-chome, Chuo-ku, Osaka |
Start of operations |
July 3, 2023 (planned) |
Number of Staff |
Approximately 420 (planned) |
The main business |
Shared services Contracted services related to the Shionogi Group’s following operations: personnel, administration, public relations, facility management, database management, accounting, finance, procurement, sales support, marketing support, education & training, career development support Safety management and post-marketing operations of the Shionogi Group as required by the Pharmaceuticals and Medical Devices Act and other regulation |
Initial Capitalization |
10 million yen |
Investment ratio |
Accenture 80%, Shionogi 20% |
Company absorbed in the Merger
Shionogi Pharmacovigilance Center Company Limited (as of February 20, 2023)
Corporate Name |
Shionogi Pharmacovigilance Center Company Limited [SPV] |
Location |
7-6, Doshomachi 4-chome, Chuo-ku, Osaka |
Representative Person |
|
Date of Establishment |
April 3, 2017 |
Number of Staff |
81 (as of January, 2023) |
Initial Capitalization |
10 million yen |
The main business |
Safety management and post-marketing operations of the Shionogi Group as required by the Pharmaceuticals and Medical Devices Act and other regulation. |
About Accenture
Accenture is a leading global professional services company that helps the world’s leading businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services—creating tangible value at speed and scale.
References
1. Press release on May 23,2022
Shionogi Announces appointment of Corporate officers, Corporate Reorganization and Personnel Reassignment
For Further Information, Contact:
SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html